Recently, TRIP13 has been found to be overexpressed in various types of cancers, including colorectal cancer [10], lung adenocarcinoma [11], ovarian cancer [12], prostate cancer [13] and head and neck cancer [14]. Here, TRIP13 is linked to cancer.